Tofacitinib in Depression (TIDE)

Sponsor
University of Oxford
Study ID
NCT04141904
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib 5 MG [Xeljanz] — DRUG
    Tofacitinib 5mg capsules twice a day for 7-10 days
  • Placebo — OTHER
    Placebo capsules twice a day for 7-10 days

Study Details

This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.

Key Dates

Start date
Feb 10, 2020
Status verified
Aug 2022
Primary completion
May 23, 2022
Completion
May 23, 2022

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Tofacitinib
    Tofacitinib 5mg capsule twice a day for 7-10 days
  • Placebo Comparator: Placebo
    Placebo capsule twice a day for 7-10 days

Primary Outcome Measure

The effects of tofacitinib on emotional processing using the Facial Expression Recognition Task (FERT) [ Time Frame: Day 7-10 of drug/placebo administration ]

Related Studies